Activity of HMR 3647 Compared to Those of Six Compounds against 235 Strains of Enterococcus faecalis

ABSTRACT Agar dilution was used to test the activities of HMR 3647, erythromycin A, azithromycin, clarithromycin, roxithromycin, clindamycin, and quinupristin-dalfopristin against 235 strains ofEnterococcus faecalis. HMR 3647 was the most active compound (MICs at which 50 and 90% of the isolates are inhibited [MIC50 and MIC90, respectively] of 0.06 and 4.0 μg/ml, respectively). The MIC50 and MIC90(with the MIC50 given first and the MIC90 given second; both in micrograms per milliliter) for other compounds were as follows: 4.0 and >32.0 for erythromycin A, 16.0 and >32.0 for azithromycin, 2.0 and >32 for clarithromycin, 32.0 and >32.0 for roxithromycin, 32.0 and >32.0 for clindamycin, and 8.0 and 16.0 for quinupristin-dalfopristin. All compounds were only bacteriostatic.

[1]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[2]  C. L. Barnes,et al.  Vancomycin-resistance enterococcus , 2000 .

[3]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[4]  G. Eliopoulos,et al.  In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria , 1997, Antimicrobial agents and chemotherapy.

[5]  R. Jones,et al.  Antimicrobial activity of RU-66647, a new ketolide. , 1997, Diagnostic microbiology and infectious disease.

[6]  H. Neu,et al.  Expanding indications for the new macrolides, azalides, and streptogramins. , 1997 .

[7]  L. Rice,et al.  Vancomycin resistance in the enterococcus. Relevance in pediatrics. , 1995, Pediatric clinics of North America.

[8]  R. Arduino,et al.  High-level resistance to aminoglycosides: comparison of community and nosocomial fecal isolates of enterococci. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Jacobs,et al.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology , 1994, Antimicrobial Agents and Chemotherapy.

[10]  M. Arthur,et al.  Genetics and mechanisms of glycopeptide resistance in enterococci , 1993, Antimicrobial Agents and Chemotherapy.

[11]  J. Duval,et al.  Vancomycin resistance gene vanC is specific to Enterococcus gallinarum , 1992, Antimicrobial Agents and Chemotherapy.

[12]  F. Tenover,et al.  Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group , 1992, Journal of clinical microbiology.

[13]  L. Rice,et al.  Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. , 1991, The Journal of infectious diseases.

[14]  G. Eliopoulos,et al.  Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. , 1990, The New England journal of medicine.

[15]  P. Courvalin.  Resistance of enterococci to glycopeptides , 1990, Antimicrobial Agents and Chemotherapy.

[16]  A. A. Goldberg,et al.  Ampicillin-resistant enterococcal species in an acute-care hospital , 1990, Antimicrobial Agents and Chemotherapy.

[17]  M. Zervos,et al.  High-level gentamicin resistance in Enterococcus: microbiology, genetic basis, and epidemiology. , 1990, Reviews of infectious diseases.

[18]  R. Springbett.  Antibiotic resistance in enterococci. , 1990, The Journal of antimicrobial chemotherapy.

[19]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[20]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[21]  C. Hill,et al.  Antimicrobial Susceptibility Patterns of Common and Unusual Species of Enterococci Causing Infections in the United States , 2022 .